Kenvue Inc. (KVUE)
| Market Cap | 38.98B |
| Revenue (ttm) | 15.49B |
| Net Income (ttm) | 1.49B |
| Shares Out | 1.91B |
| EPS (ttm) | 0.78 |
| PE Ratio | 26.10 |
| Forward PE | 17.06 |
| Dividend | $0.80 (3.93%) |
| Ex-Dividend Date | May 7, 2024 |
| Volume | 20,702,708 |
| Open | 20.30 |
| Previous Close | 20.54 |
| Day's Range | 20.17 - 20.79 |
| 52-Week Range | 17.82 - 27.80 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 24.23 (+19.01%) |
| Earnings Date | May 7, 2024 |
About KVUE
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Ma... [Read more]
Financial Performance
In 2023, Kenvue's revenue was $15.44 billion, an increase of 3.30% compared to the previous year's $14.95 billion. Earnings were $1.66 billion, a decrease of -19.38%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price forecast is $24.23, which is an increase of 19.01% from the latest price.
News
Kenvue's stock falls after company announces 182.3 million secondary stock offering
Kenvue Inc.'s stock fell 1.8% early Monday, after the consumer-health business, which was spun out of Johnson & Johnson last year, announced plans for a secondary offering of 182.3 million shares.
J&J to exit Kenvue, a year after spinoff
Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health bus...
Kenvue Announces Launch of Secondary Offering
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announced today the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock.
Kenvue's stock jumps 4.7% after earnings beat and news company to cut 4% of global workforce
Kenvue Inc.'s stock KVUE, -0.63% jumped 4.7% early Tuesday, after the consumer health business that was spun out of Johnson & Johnson last year posted better-than-expected first-quarter earnings and a...
Tylenol maker Kenvue beats quarterly profit estimates, to cut 4% jobs
Kenvue beat Wall Street estimates for first-quarter profit on Tuesday, and said it would cut 4% of its global workforce amid the Tylenol and Band-Aid maker's efforts to expand its key brands.
Kenvue Reports First Quarter 2024 Results
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal first quarter ended March 31, 2024. “We entered 2024 with clear strategic priorit...
Kenvue Declares Quarterly Cash Dividend
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue today announced a dividend payable in Q2 of $0.20 per share on the Company's common stock. The dividend is payable on May 22, 2024.
Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit
An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relati...
Here's why Harris' Alex Fitch favors Kenvue
Alex Fitch, Harris Associates director of U.S. Research, joins 'Money Movers' to discuss Fitch's investment thesis towards Delta Air Lines, whether investors are not supposed to buy cyclical stocks at...
Kenvue to Announce First Quarter 2024 Results on May 7, 2024
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue, the world's largest pure-play consumer health company by revenue, will announce its 2024 Q1 results before market open on May 7, 2024.
Kenvue to Showcase 22 New Sets of Clinical Data at American Academy of Dermatology Association Meeting
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. will share new data at the American Academy of Dermatology (AAD) Association Annual Meeting.
David Einhorn's Greenlight Capital adds Kenvue, ETFs and exits Southwestern Energy
David Einhorn's hedge fund Greenlight Capital picked up a new stake in Kenvue Inc. KVUE — formerly the consumer healthcare division of Johnson & Johnson JNJ — in the fourth quarter, according to a pub...
Kenvue to Present at the Consumer Analyst Group of New York Conference on February 23, 2024
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue CEO and CFO to present at the Consumer Analyst Group of New York (CAGNY) Conference on February 23, 2024 at 10 a.m. EST.
J&J spinoff Kenvue stock loses ground as profit drops
Kenvue Inc.'s stock KVUE, -0.39% fell by 3.2% in premarket trading on Thursday after the household products spin-off of Johnson & Johnson JNJ, -0.05% reported lower fourth-quarter profit and said its ...
Tylenol maker Kenvue forecasts annual profit below estimates after weak quarter
Kenvue forecast full-year profit below analysts' expectations after missing quarterly sales estimates on Thursday, as the Tylenol maker faces sluggish demand in China and slowing growth for skin and b...
Kenvue Reports Full Year and Fourth Quarter 2023 Results
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”), today announced financial results for the fiscal full year and fourth quarter ended December 31, 2023.
3 Top Value Stocks to Buy and Hold for 2024
These high-quality companies are solid—and their stocks look cheap.
3 Dividend Stocks for January 2024
The dividend prospects of three firms with wide or narrow Morningstar Economic Moat Ratings.
Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce financial results for the fourth quarter and full year ending December 31, 2023, on February 8, 2024.
Lawsuits claiming Tylenol causes autism lack scientific support, judge finds
Dec 19 (Reuters) - A judge has barred expert witnesses from testifying that Johnson & Johnson (JNJ.N) spin-off Kenvue's (KVUE.N) painkiller Tylenol can cause autism if mothers take it during pregnancy...
Kenvue Shares Are Rising. Tylenol Litigation Fades Into the Rearview.
A ruling hurts litigation against Kenvue that alleges a link between prenatal exposure to the company's Tylenol and autism spectrum disorder or ADHD.
Kenvue shares rise after favorable court ruling in Tylenol litigation
Shares of Tylenol maker Kenvue Inc. KVUE, +0.10% gained more than 5% premarket on Tuesday after a federal court judge in New York ruled that plaintiffs' expert testimony will be blocked in a case invo...
Kenvue: A High-Quality Consumer Health Company on Sale
In May, Kenvue Inc. (KVUE, Financial) successfully concluded its separation from Johnson & Johnson (JNJ, Financial); however, its stock has experienced a decline about 25% since the completion of this...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Kenvue Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kenvue Inc. ("Kenvue" or "t...
KVUE DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action Commenced by the Firm – KVUE
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kenvue Inc. (NYSE: KVUE) pursuant and/or traceable to the registration statem...